Literature DB >> 25949861

Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.

Mads Duus Hjortsø1, Stine Kiaer Larsen1, Per Kongsted1, Özcan Met1, Thomas Mørch Frøsig1, Gitte Holmen Andersen1, Shamaila Munir Ahmad1, Inge Marie Svane1, Jürgen C Becker2, Per Thor Straten1, Mads Hald Andersen1.   

Abstract

Tryptophan-2,3-dioxygenase (TDO) physiologically regulates systemic tryptophan levels in the liver. However, numerous studies have linked cancer with activation of local and systemic tryptophan metabolism. Indeed, similar to other heme dioxygenases TDO is constitutively expressed in many cancers. In the present study, we detected the presence of both CD8+ and CD4+ T-cell reactivity toward TDO in peripheral blood of patients with malignant melanoma (MM) or breast cancer (BC) as well as healthy subjects. However, TDO-reactive CD4+ T cells constituted distinct functional phenotypes in health and disease. In healthy subjects these cells predominately comprised interferon (IFN)γ and tumor necrosis factor (TNF)-α producing Th1 cells, while in cancer patients TDO-reactive CD4+ T-cells were more differentiated with release of not only IFNγ and TNFα, but also interleukin (IL)-17 and IL-10 in response to TDO-derived MHC-class II restricted peptides. Hence, in healthy donors (HD) a Th1 helper response was predominant, whereas in cancer patients CD4+ T-cell responses were skewed toward a regulatory T cell (Treg) response. Furthermore, MM patients hosting a TDO-specific IL-17 response showed a trend toward an improved overall survival (OS) compared to MM patients with IL-10 producing, TDO-reactive CD4+ T cells. For further characterization, we isolated and expanded both CD8+ and CD4+ TDO-reactive T cells in vitro. TDO-reactive CD8+ T cells were able to kill HLA-matched tumor cells of different origin. Interestingly, the processed and presented TDO-derived epitopes varied between different cancer cells. With respect to CD4+ TDO-reactive T cells, in vitro expanded T-cell cultures comprised a Th1 and/or a Treg phenotype. In summary, our data demonstrate that the immune modulating enzyme TDO is a target for CD8+ and CD4+ T cell responses both in healthy subjects as well as patients with cancer; notably, however, the functional phenotype of these T-cell responses differ depending on the respective conditions of the host.

Entities:  

Keywords:  T cells; TDO; Th17; Tregs; immune regulation

Year:  2015        PMID: 25949861      PMCID: PMC4368150          DOI: 10.4161/21624011.2014.968480

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  36 in total

Review 1.  Selection of self-reactive T cells in the thymus.

Authors:  Gretta L Stritesky; Stephen C Jameson; Kristin A Hogquist
Journal:  Annu Rev Immunol       Date:  2011-12-05       Impact factor: 28.527

Review 2.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

3.  IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma.

Authors:  Wen-Wei Sung; Yao-Chen Wang; Po-Lin Lin; Ya-Wen Cheng; Chih-Yi Chen; Tzu-Chin Wu; Huei Lee
Journal:  Clin Cancer Res       Date:  2013-06-06       Impact factor: 12.531

4.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.

Authors:  Christiane A Opitz; Ulrike M Litzenburger; Felix Sahm; Martina Ott; Isabel Tritschler; Saskia Trump; Theresa Schumacher; Leonie Jestaedt; Dieter Schrenk; Michael Weller; Manfred Jugold; Gilles J Guillemin; Christine L Miller; Christian Lutz; Bernhard Radlwimmer; Irina Lehmann; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

5.  JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Authors:  H Quentmeier; R A F MacLeod; M Zaborski; H G Drexler
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

6.  Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.

Authors:  Rikke Bæk Sørensen; Tania Køllgaard; Rikke Sick Andersen; Joost Huibert van den Berg; Inge Marie Svane; Per thor Straten; Mads Hald Andersen
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

7.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

Review 8.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

10.  The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

Authors:  Rikke Baek Sørensen; Linda Berge-Hansen; Niels Junker; Christina Aaen Hansen; Sine Reker Hadrup; Ton N M Schumacher; Inge Marie Svane; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
Journal:  PLoS One       Date:  2009-09-07       Impact factor: 3.240

View more
  13 in total

1.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.

Authors:  Mads Hald Andersen
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

Review 2.  Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.

Authors:  Mayanne M T Zhu; Amanda R Dancsok; Torsten O Nielsen
Journal:  Curr Oncol Rep       Date:  2019-01-18       Impact factor: 5.075

Review 3.  The role of transforming growth factor-beta in immune suppression and chronic inflammation of squamous cell carcinomas.

Authors:  Alexander A Strait; Xiao-Jing Wang
Journal:  Mol Carcinog       Date:  2020-04-17       Impact factor: 4.784

Review 4.  Tumor microenvironment antigens.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2022-09-29       Impact factor: 11.759

Review 5.  The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies.

Authors:  Hamed Hosseinalizadeh; Mehrdad Mahmoodpour; Ali Akbar Samadani; Mehryar Habibi Roudkenar
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.738

Review 6.  Anti-regulatory T cells.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2016-09-27       Impact factor: 9.623

Review 7.  Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.

Authors:  George C Prendergast; Arpita Mondal; Souvik Dey; Lisa D Laury-Kleintop; Alexander J Muller
Journal:  Trends Cancer       Date:  2017-12-21

Review 8.  The T-win® technology: immune-modulating vaccines.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2018-07-02       Impact factor: 9.623

Review 9.  Not Only Immune Escape-The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis.

Authors:  Iwona Kwiatkowska; Justyna Magdalena Hermanowicz; Alicja Przybyszewska-Podstawka; Dariusz Pawlak
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

10.  Th17 Cells in Protection from Tumor or Promotion of Tumor Progression.

Authors:  M Rita I Young
Journal:  J Clin Cell Immunol       Date:  2016-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.